Plus Therapeutics (PSTV) Price & Analysis

Compare

1,121 Followers

PSTV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.16 - $2.31

Previous CloseN/A

Volume69.06K

Average Volume (3M)15.89M

Market Cap

$50.15M

Enterprise Value$65.90M

Total Cash (Recent Filing)$9.87M

Total Debt (Recent Filing)$40.00K

Price to Earnings (P/E)―

Beta2.44

Next Earnings

Oct 16, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding99,264,530

10 Day Avg. Volume9,498,442

30 Day Avg. Volume15,885,430

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.31

Enterprise Value/Revenue28.18

Enterprise Value/Gross Profit-106.97

Enterprise Value/Ebitda-3.48

Forecast

1Y Price Target

$6.75

Price Target Upside1277.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe ReSPECT-GBM trial reports positive results, with a median overall survival of 11 months, exceeding the standard of care.

Financial PositionThe company has a solid balance sheet with $10 million in cash and no debt, and it raised $18 million in Q1, providing enough financial resources into 2026.

Product LaunchThe upcoming launch of the CNSide platform, a novel diagnostic tool for leptomeningeal metastases, is expected to be a major positive for the stock.

Bears Say

Operational CostsAn agreement with an investor for the purchase of up to 17 million shares of stock would help the company cover operational costs associated with the launch of CNSide.

Revenue PerformanceThe company reported $1.0M in grant revenues in 1Q25, compared to consensus estimated revenue of $1.5M, and a net loss of $1.19 per share, compared to consensus estimated net loss of $0.25 per share.

Plus Therapeutics News

Plus Therapeutics regains compliance with applicable Nasdaq listing criteria

Plus Therapeutics (PSTV) announced that it received a letter from Nasdaq on August 22, 2025, confirming its compliance...

3d ago

PSTV

Plus Therapeutics price target lowered to $3 from $4 at Maxim

Maxim lowered the firm’s price target on Plus Therapeutics (PSTV) to $3 from $4 and keeps a Buy...

11d ago

PSTV

Plus Therapeutics presents results from ReSPECT-LM Phase 1 trial

Plus Therapeutics (PSTV) announces positive data from the ReSPECT-LM Phase 1 single dose escalation trial presented at the...

11d ago

PSTV

Plus Therapeutics reports stockholders’ equity in excess of $2.5M

Plus Therapeutics (PSTV) announced it reported stockholders’ equity of $3M and therefore satisfied Nasdaq Listing Rule 5550(b)(1), as...

14d ago

PSTV

Plus Therapeutics presents data from analysis of CNSide CSF Assay

Plus Therapeutics (PSTV) announced positive data from a retrospective analysis of the CNSide Cerebrospinal Fluid, CSF, Assay Platform...

15d ago

PSTV

Plus Therapeutics files to sell 33M shares of common stock for holders

16:09 EDT Plus Therapeutics (PSTV) files to sell 33M shares of common stock for holders Published first on...

16d ago

PSTV

Plus Therapeutics says CNSide CSF platform will be available for Texas in August

Plus Therapeutics (PSTV) announces that its wholly-owned subsidiary, CNSide Diagnostics will make CNSide cerebrospinal fluid assay platform and...

29d ago

PSTV

Plus Therapeutics Secures Nasdaq Compliance Extension

Plus Therapeutics ( ($PSTV) ) has shared an update. On August 22, 2025, Plus Therapeutics, Inc. received confirmation...

3d ago

PSTV

Optimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements

Maxim Group analyst Jason McCarthy has maintained their bullish stance on PSTV stock, giving a Buy rating yesterday....

12d ago

PSTV

Buy Rating for Plus Therapeutics: Strategic Market Launch and Promising Financial Outlook

Sean Lee CFA, an analyst from H.C. Wainwright, maintained the Buy rating on Plus Therapeutics. The associated price...

14d ago

PSTV

Plus Therapeutics Reports Strong Q2 2025 Results

Plus Therapeutics ( ($PSTV) ) has released its Q2 earnings. Here is a breakdown of the information Plus...

14d ago

PSTV

Plus Therapeutics Awaits Nasdaq Compliance Confirmation

Plus Therapeutics ( ($PSTV) ) has provided an update. On June 3, 2025, Plus Therapeutics was notified by...

14d ago

PSTV

Plus Therapeutics Granted Continued Nasdaq Listing

An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 3, 2025, Plus Therapeutics was...

16d ago

PSTV

Plus Therapeutics Approves Key Proposals at Annual Meeting

An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On August 7, 2025, Plus Therapeutics held...

16d ago

PSTV

PSTV FAQ

What was Plus Therapeutics Inc’s price range in the past 12 months?

Plus Therapeutics Inc lowest stock price was $0.16 and its highest was $2.31 in the past 12 months.

What is Plus Therapeutics Inc’s market cap?

Plus Therapeutics Inc’s market cap is $50.15M.

When is Plus Therapeutics Inc’s upcoming earnings report date?

Plus Therapeutics Inc’s upcoming earnings report date is Oct 16, 2025 which is in 48 days.

How were Plus Therapeutics Inc’s earnings last quarter?

Plus Therapeutics Inc released its earnings results on Aug 14, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.11.

Is Plus Therapeutics Inc overvalued?

According to Wall Street analysts Plus Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Plus Therapeutics Inc pay dividends?

Plus Therapeutics Inc does not currently pay dividends.

What is Plus Therapeutics Inc’s EPS estimate?

Plus Therapeutics Inc’s EPS estimate is -0.05.

How many shares outstanding does Plus Therapeutics Inc have?

Plus Therapeutics Inc has 99,264,530 shares outstanding.

What happened to Plus Therapeutics Inc’s price movement after its last earnings report?

Plus Therapeutics Inc reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 16.667%.

Which hedge fund is a major shareholder of Plus Therapeutics Inc?

Currently, no hedge funds are holding shares in PSTV

Plus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

249.03%

Trailing 12-Months

Asset Growth

-7.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Plus Therapeutics (PSTV) Earnings & Revenues

Historic Earnings Reports

PSTV Stock 12 Month Forecast

Average Price Target

$6.75

▲(1277.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.58,2.1123076923076924,3.644615384615385,5.176923076923077,6.7092307692307696,8.241538461538461,9.773846153846154,11.306153846153846,12.838461538461539,14.370769230769232,15.903076923076924,17.435384615384613,18.967692307692307,{"y":20.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.58,1.0546153846153845,1.5292307692307692,2.003846153846154,2.4784615384615383,2.953076923076923,3.4276923076923076,3.9023076923076925,4.3769230769230765,4.851538461538461,5.326153846153846,5.800769230769231,6.275384615384615,{"y":6.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.58,0.5738461538461538,0.5676923076923076,0.5615384615384615,0.5553846153846154,0.5492307692307692,0.543076923076923,0.536923076923077,0.5307692307692308,0.5246153846153846,0.5184615384615384,0.5123076923076924,0.5061538461538462,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.99,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.58,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >